Is there treatment for 'genetic' disease?

Molecular Genetics and Metabolism

Volumn 68, Issue 2, 1999, Pages 93-102

  Scriver, Charles R ^a   Treacy, Eileen P ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PAMIDRONIC ACID; PHENYLALANINE AMMONIA LYASE;

CYSTIC FIBROSIS; DRUG THERAPY; GENE THERAPY; GENETIC DISORDER; HYPERTROPHIC CARDIOMYOPATHY; INSULIN DEPENDENT DIABETES MELLITUS; NIEMANN PICK DISEASE; OSTEOGENESIS IMPERFECTA; PHENYLKETONURIA; PRIORITY JOURNAL; SHORT SURVEY; SMITH LEMLI OPITZ SYNDROME; SURGERY; TAY SACHS DISEASE; TISSUE TRANSPLANTATION; TYROSINEMIA;

EID: 0032759157     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.1999.2907     Document Type: Article

References (71)

1. Cannon W B. The Wisdom of the Body. 1932;Norton, New York.
2. Murphy E A. The dynamics of quantifiable homeostasis. VI: Processes of fractional order. Am J Med Genet. 21:1985;385-394.
3. N Engl J Med. 329:1993;977-986.
4. Scriver C R, Kaufman S, Eisensmith R C, Woo S LC. The Hyperphenylalaninemias. Scriver CR Beaudet AL, Sly WS Valle D. The Metabolic and Molecular Bases of Inherited Disease. 1995;1015-1075 McGraw-Hill, New York.
5. Br Med J. 306:1993;115-119.
6. Arch Dis Childhood. 68:1993;126-127.
7. Riva E, Agostoni C, Biasucci G, Trojan S, Luotti D, Fiori L, Giovannini M. Early breastfeeding is linked to higher intelligence quotient scores in dietary treated phenylketonuric children. Acta Paediatr. 85:1996;56-58.
8. Sarkissian C N, Shao Z, Blain F. A different approach to treatment of phenylketonuria: Phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci USA. 96:1999;2339-2344.
9. Levy H L. Commentary - Phenylketonuria: Old disease, new approach to treatment. Proc Natl Acad Sci USA. 96:1999;1811-1813.
10. Brown M S, Goldstein J L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
11. Lindstedt S, Holme E, Lock E A, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 340:1992;813-817.
12. Mitchell, G, A, Grompe, M, Lambert, M, Tanguay, R, M, Hypertyrosinemia. In, The Metabolic and Molecular Bases of Inherited Disease, 8th ed. (, Scriver, C, R, Beaudet, A, L, Sly, W, S, Valle, D, Vogelstein, B, Childs, B, Eds.), New York, McGraw-Hill. [in press].
13. Glorieux F H, Bishop N J, Plotkin H, Chabot G, Lanome G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 339:1998;947-952.
14. Plunkett M J, Ellman J A. Combinatorial chemistry and new drugs. Sci Am. 1997;68-73.
15. Garrod A E. The Croonian Lectures. Inborn errors of metabolism. Lancet. 2:1908;1-7.
16. Bickel H, Gerrard J, Hickmans E M. Influence of phenylalanine intake on phenylketonuria. Lancet. 2:1953;812.
17. Rattazzi M C, Dobrenis K. Enzyme replacement: Overview and prospects. Desnick R J. Treatment of Genetic Diseases. 1991;131-149 Churchill Livingstone.
18. Platt J L. New directions for organ transplantation. Nature. 392:1998;11-17.
19. Solter D, Gearhart J. Putting stem cells to work. Science. 283:1999;1468-1470.
20. Gerson S L. Mesenchymal stem cells: No longer second class citizens. Nature Med. 5:1999;262-263.
21. Friedmann T. Overcoming the obstacles to gene therapy. Sci Am. 276:1997;96-101.
22. Kay M A, Liu D, Hoogerbruhgge P M. Gene therapy. Proc Natl Acad Sci USA. 94:1997;12744-12746.
23. Anderson W F. Human gene therapy. Nature. 392:1998;25-30.
24. Blau H, Khavari P. Gene therapy: Progress, problems, prospects. Nature Med. 3:1997;612-613.
25. Touchette N. Gene therapy: Not ready for prime time. Nature Med. 2:1996;7-8.
26. Green A, Pollitt R J. Population newborn screening for inherited metabolic disease: Current UK perspectives. J Inher Metab Dis. 22:1999;572-579.
27. Thomason M J, Lord J, Bain M D, Chalmers R A, Littlejohns P, Addison G M, Wilcox A H, Seymour C A. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. J Pub Health Med. 20:1998;331-343.
28. Cederbaum S, Vilain E. Newborn screening for inborn errors of metabolism is going to expand: Are we ready. J Pediatr. 134:1999;666-667.
29. Lord J, Thomason M J, Littlejohns P, Chalmers R A, Bain M D, Addison G M, Wilcox A H, Seymour C A. Secondary analysis of economic data: A review of cost-benefit studies of neonatal screening for phenylketonuria. J Epidemiol Community Health. 53:1999;179-185.
30. Thomas E D. Does bone marrow transplantation confer a normal life span. N Engl J Med. 341:1999;50-51.
31. Treacy, E, P, Valle, D, Scriver, C, R, Treatment of genetic disease. In, The Metabolic and Molecular Bases of Inherited Disease, 8th ed. (, Scriver, C, R, Beaudet, A, L, Sly, W, S, Valle, D, Vogelstein, B, Childs, B, Eds.), New York, McGraw-Hill. [in press].
32. Hayes A, Costa T, Scriver C R, Childs B. The effect of Mendelian disease on human health. Am J Med Genet. 21:1985;243-255.
33. Costa T, Scriver C R, Childs B. The effect of Mendelian disease on human health: A measurement. Am J Med Genet. 21:1985;231-242.
34. Treacy E, Childs B, Scriver C R. Response to treatment in hereditary metabolic disease: 1993 survey and 10-year comparison. Am J Hum Genet. 56:1995;359-367.
35. Thoene J G. Current status of orphan disease drug development. Curr Opin Pediatr. 6:1994;209-212.
36. Scriver C R, Waters P J. Monogenic traits are not simple: Lessons from phenylketonuria. Trends Genet. 15:1999;267-292.
37. Grabowski G A, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: The first 5 years. Blood Rev. 12:1998;115-133.
38. Kakkis E D, McEntee M F, Schmidtchen A, Neufeld E F, Ward D A, Gompf R E, Kania S, Bedolla C, Chien S L, Shull R M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med. 58:1996;156-167.
39. Kakkis E, Muenzer J, Tiller G, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Walot I, Doroshow R, Hoft R, Yu K T, Okasaki S, Lewis D, Lachman R, Neufeld E F. Recombinant α-L-iduronidase replacement therapy in mucopolysaccharidosis I: Results of a human clinical trial. Am J Hum Genet. 63:1998;A25.
40. O'Connor L H, Erway L C, Vogler C A, Sly W AS, Nicholes A, Grubb J, Homberg S W, Levy B, Sands M S. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behaviour and auditory function. J Clin Invest. 101:1998;1394-1400.
41. Kikuchi T, Yang H W, Pennybacker M, Ichihwa N, Mizutani M, Van Hove J LK, Chen Y-T. Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest. 101:1998;827-833.
42. Peters C, Shapiro E G, Krivit W. Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation. Pediatr Transplant. 9:1998;14.
43. Broxmeyer H E. Cord blood transplantation study standard operating procedures: an evolving document will improve cord blood unit quality. J Hemother. 6:1998;479-480.
44. Horwitz E M, Prockop D J, Fitzpatrick L A, Koo W WK, Gordon L P, Neel M, Sussman M, Orchard P, Marx J C, Pyeritz R E, Brenner M K. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nature Med. 5:1999;309-313.
45. Collins F S. Shattuck Lecture - Medical and societal consequences of the Human Genome Project. N Engl J Med. 341:1999;28-37.
46. Delaney S J, Wainwright B J. New pharmaceutical approaches to the treatment of cystic fibrosis. Nature Med. 2:1996;392-393.
47. Howard M, Frizzell R A, Bedwell D M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Med. 2:1996;467-469.
48. Dietz H C, Hamosh A. Non-stop treatment of cystic fibrosis. Nature Med. 2:1996;608.
49. Kubo S, Sun M, Miyahara M, Umeyama K, Urakami K-I, Yamamoto T, Jakobs C, Matsuda I, Endo F. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA. 95:1998;9552-9557.
50. Sussman M A, Lim H W, Gude N, Taigen T, Olson E N, Robbins J, Colbert M C, Gualberto A, Wieczorek D F, Molkentin J D. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 281:1998;1690-1693.
51. Sango K, Yamanaka A, Hoffman A, Okuda Y, Grinberg A, Westphal H, McDonald M P, Crawley J N, Sandhoff K, Suzuki K. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. 11:1995;170-176.
52. Phaneuf D, Wakamatsu N, Huang J Q, Borowski A, Peterson A C, Fortunato S R, Ritter G, Igdoura S A, Morales C R, Benoit G, Akerman B R, Leclerc D, Hanai N, Marth J D, Trasler J M, Gravel R A. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet. 5:1996;1-14.
53. Igdoura S A, Mertineit C, Trasler J M, Gravel R A. Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells. Hum Mol Genet. 6:1999;1111-1116.
54. Freeze H H. Disorders in protein glycosylation and potential therapy: Tip of an iceberg. J Pediatr. 133:1998;593-600.
55. Niehues R, Hasilik M, Alton G, Korner C, Schiebe-Sukumar M, Koch H G, Zimmer K-P, Wu R, Harms E, Reiter K, von Figura K, Freeze H H, Harms H K, Marquardt T. Carbohydrate-deficient glycoprotein syndrome type Ib: Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest. 101:1998;1414-1420.
56. Freeze H H. Human glycosylation disorders and sugar supplement therapy. Biochem Biophys Res Commun. 255:1999;189-193.
57. Kelley R I. RSH/Smith-Lemli-Opitz syndrome: Mutations and metabolic morphogenesis. Am J Hum Genet. 63:1998;322-326.
58. Irons M, Elias E R, Abuelo D, Bull M J, Greene C L, Johnson V P, Keppen L, Schanen C, Tint G S, Salen G. Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. Am J Med Genet. 68:1997;311-314.
59. Linck, L, Lin, D, Connor, W, E, Steiner, R, D, Cholesterol supplementation with egg yolk decreases plasma 7-dehydrocholesterol in Smith-Lemli-Opitz syndrome, Am J Hum Genet, 63: A270, 1998, [abstract No. 1555].
60. Kelley R I, Wilcox W G, Smith M, Kratz L E, Moser A, Rimoin D S. Abnormal sterol metabolism in patients with Conradi-Hunermann-Happle syndrome and sporadic lethal chondrodysplasia punctata. Am J Hum Genet. 83:1999;213-219.
61. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 33:1992;1569-1582.
62. Brown M S, Goldstein J L. Heart attacks: Gone with the century. Science. 272:1996;629.
63. Sylvain M, Arnold D L, Scriver C R, Schreiber R, Shevell M I. Magnetic resonance spectroscopy in Niemann-Pick Disease Type C: Correlation with diagnosis and clinical response to Cholestyramine and lovastatin. Pediatr Neurol. 10:1994;228-232.
64. Singh I, Khan M, Key L, Pai S. Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med. 339:1998;702-703.
65. Kemp S, Wei H-M, Lu J-F, Braiterman L T, McGuiness M C, Moser A B, Watkins P A, Smith K D. Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystropy. Nature Med. 4:1998;1261-1268.
66. Pardes H, Manton K G, Lander E S, Tolley H D, Ullian A D, Palmer H. Effects of medical research on health care and the economy. Science. 283:1999;36-37.
67. Goldstein J L, Brown M S. The clinical investigator: bewitched, bothered, and bewildered - but still beloved. J Clin Invest. 99:1997;2803-2812.
68. Charlton B G. Commentary: Natural kinds, natural history and the clinician-researcher. Quart J Med. 90:1997;707-709.
69. Flowers C R, Melman K L. Clinical investigators as critical determinants in pharmaceutical innovation. Nature Med. 3:1997;136-143.
70. Garrod A E. The incidence of Alkaptonuria: A study in chemical individuality. Lancet. 2:1902;1616-1620.
71. Garrod A E. Scriver CR Childs B. The Inborn Factors in Diseases: An Essay. 1931;Clarendon Press, Oxford.